vs
Side-by-side financial comparison of Fidelity National Financial, Inc. (FNF) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Medpace Holdings, Inc. is the larger business by last-quarter revenue ($708.5M vs $544.0M, roughly 1.3× Fidelity National Financial, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs -21.5%, a 40.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 10.3%). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 13.7%).
Fidelity National Financial, Inc., is an American provider of title insurance and settlement services to the real estate and mortgage industries. A Fortune 500 company, Fidelity National Financial generated approximately $8.469 billion in annual revenue in 2019 from its title and real estate-related operations. The company was the first instance of an attorney licensed by a Native American Tribe being certified as "authorized house counsel" in the state of Florida.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
FNF vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $544.0M | $708.5M |
| Net Profit | $-117.0M | $135.1M |
| Gross Margin | — | — |
| Operating Margin | 82.9% | 21.6% |
| Net Margin | -21.5% | 19.1% |
| Revenue YoY | 10.3% | 32.0% |
| Net Profit YoY | -126.0% | 15.5% |
| EPS (diluted) | $-0.44 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $544.0M | $708.5M | ||
| Q3 25 | $553.0M | $659.9M | ||
| Q2 25 | $547.0M | $603.3M | ||
| Q1 25 | $455.0M | $558.6M | ||
| Q4 24 | $493.0M | $536.6M | ||
| Q3 24 | $506.0M | $533.3M | ||
| Q2 24 | $504.0M | $528.1M | ||
| Q1 24 | $421.0M | $511.0M |
| Q4 25 | $-117.0M | $135.1M | ||
| Q3 25 | $358.0M | $111.1M | ||
| Q2 25 | $278.0M | $90.3M | ||
| Q1 25 | $83.0M | $114.6M | ||
| Q4 24 | $450.0M | $117.0M | ||
| Q3 24 | $266.0M | $96.4M | ||
| Q2 24 | $306.0M | $88.4M | ||
| Q1 24 | $248.0M | $102.6M |
| Q4 25 | 82.9% | 21.6% | ||
| Q3 25 | 81.9% | 21.5% | ||
| Q2 25 | 69.8% | 20.9% | ||
| Q1 25 | 24.4% | 20.3% | ||
| Q4 24 | — | 23.4% | ||
| Q3 24 | 61.9% | 21.1% | ||
| Q2 24 | 90.9% | 19.9% | ||
| Q1 24 | 78.6% | 20.4% |
| Q4 25 | -21.5% | 19.1% | ||
| Q3 25 | 64.7% | 16.8% | ||
| Q2 25 | 50.8% | 15.0% | ||
| Q1 25 | 18.2% | 20.5% | ||
| Q4 24 | 91.3% | 21.8% | ||
| Q3 24 | 52.6% | 18.1% | ||
| Q2 24 | 60.7% | 16.7% | ||
| Q1 24 | 58.9% | 20.1% |
| Q4 25 | $-0.44 | $4.65 | ||
| Q3 25 | $1.33 | $3.86 | ||
| Q2 25 | $1.02 | $3.10 | ||
| Q1 25 | $0.30 | $3.67 | ||
| Q4 24 | $1.65 | $3.67 | ||
| Q3 24 | $0.97 | $3.01 | ||
| Q2 24 | $1.12 | $2.75 | ||
| Q1 24 | $0.91 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.6B | $497.0M |
| Total DebtLower is stronger | $4.4B | — |
| Stockholders' EquityBook value | $7.4B | $459.1M |
| Total Assets | $109.0B | $2.0B |
| Debt / EquityLower = less leverage | 0.59× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.6B | $497.0M | ||
| Q3 25 | $3.5B | $285.4M | ||
| Q2 25 | $3.3B | $46.3M | ||
| Q1 25 | $4.5B | $441.4M | ||
| Q4 24 | $3.5B | $669.4M | ||
| Q3 24 | $5.0B | $656.9M | ||
| Q2 24 | $4.9B | $510.9M | ||
| Q1 24 | $3.5B | $407.0M |
| Q4 25 | $4.4B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.4B | — | ||
| Q1 25 | $4.4B | — | ||
| Q4 24 | $4.3B | — | ||
| Q3 24 | $4.2B | — | ||
| Q2 24 | $4.2B | — | ||
| Q1 24 | $3.9B | — |
| Q4 25 | $7.4B | $459.1M | ||
| Q3 25 | $8.4B | $293.6M | ||
| Q2 25 | $7.9B | $172.4M | ||
| Q1 25 | $7.9B | $593.6M | ||
| Q4 24 | $7.8B | $825.5M | ||
| Q3 24 | $8.1B | $881.4M | ||
| Q2 24 | $7.3B | $763.6M | ||
| Q1 24 | $7.1B | $671.5M |
| Q4 25 | $109.0B | $2.0B | ||
| Q3 25 | $106.6B | $1.8B | ||
| Q2 25 | $102.3B | $1.6B | ||
| Q1 25 | $98.2B | $1.9B | ||
| Q4 24 | $95.4B | $2.1B | ||
| Q3 24 | $94.7B | $2.1B | ||
| Q2 24 | $88.8B | $1.9B | ||
| Q1 24 | $84.5B | $1.8B |
| Q4 25 | 0.59× | — | ||
| Q3 25 | 0.53× | — | ||
| Q2 25 | 0.56× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.56× | — | ||
| Q3 24 | 0.52× | — | ||
| Q2 24 | 0.58× | — | ||
| Q1 24 | 0.55× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.5B | $192.7M |
| Free Cash FlowOCF − Capex | — | $188.1M |
| FCF MarginFCF / Revenue | — | 26.6% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | — | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.5B | $192.7M | ||
| Q3 25 | $1.3B | $246.2M | ||
| Q2 25 | $1.9B | $148.5M | ||
| Q1 25 | $1.1B | $125.8M | ||
| Q4 24 | $1.5B | $190.7M | ||
| Q3 24 | $2.4B | $149.1M | ||
| Q2 24 | $1.4B | $116.4M | ||
| Q1 24 | $1.6B | $152.7M |
| Q4 25 | — | $188.1M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | — | $142.4M | ||
| Q1 25 | — | $115.8M | ||
| Q4 24 | — | $183.0M | ||
| Q3 24 | — | $138.5M | ||
| Q2 24 | — | $103.5M | ||
| Q1 24 | — | $147.2M |
| Q4 25 | — | 26.6% | ||
| Q3 25 | — | 35.7% | ||
| Q2 25 | — | 23.6% | ||
| Q1 25 | — | 20.7% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | — | 26.0% | ||
| Q2 24 | — | 19.6% | ||
| Q1 24 | — | 28.8% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 1.4% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 1.43× | ||
| Q3 25 | 3.66× | 2.22× | ||
| Q2 25 | 6.82× | 1.65× | ||
| Q1 25 | 13.43× | 1.10× | ||
| Q4 24 | 3.32× | 1.63× | ||
| Q3 24 | 8.89× | 1.55× | ||
| Q2 24 | 4.45× | 1.32× | ||
| Q1 24 | 6.42× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
